Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 6,74 M
EBIT 2017 -0,75 M
Net income 2017 -1,06 M
Debt 2017 -
Yield 2017 -
Sales 2018 8,04 M
EBIT 2018 -2,23 M
Net income 2018 -2,59 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 7,62x
Capi. / Sales2018 6,38x
Capitalization 51,3 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Surperformance© ratings of IntelGenx Technologies Cor
Trading Rating : - Investor Rating :
More Ratings
Latest news on INTELGENX TECHNOLOGIES COR
05/11 INTELGENX TECHNOLOGIES : reports 1Q loss
05/11 INTELGENX TECHNOLOGIES CORP. (OTCMKT : IGXT) Files An 8-K Other Events
05/11 INTELGENX TECHNOLOGIES CORP. : Management's Discussion and Analysis of Financial..
05/11 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
05/11 INTELGENX TECHNOLOGIES : Reports First Quarter 2017 Financial Results
05/11 INTELGENX TECHNOLOGIES : Reports First Quarter 2017 Financial Results
05/11 INTELGENX TECHNOLOGIES CORP. : Investor Network: Intelgenx Technologies Corp. to..
05/10 INTELGENX TECHNOLOGIES CORP. (OTCMKT : IGXT) Files An 8-K Submission of Matters ..
05/10 INTELGENX TECHNOLOGIES CORP. : Submission of Matters to a Vote of Security Holde..
05/04 INTELGENX TECHNOLOGIES : to Report First Quarter 2017 Financial Results on May 1..
More news
Sector news : Generic Pharmaceuticals
02:15p UK competition watchdog accuses Merck of obstructing biosimilars
08:35aDJASTRAZENECA : Says Bydureon Trial Meets Safety Objectives; No Significant CV Red..
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
05/19 European shares claw back gains after worst week in six months
More sector news : Generic Pharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 91%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Horst G. Zerbe Chairman, President & Chief Executive Officer
André Godin Chief Financial Officer & Executive Vice President
Nadine Paiement Director-Research & Development
Bernd Josef Melchers Independent Director
John Archibald Troup Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INTELGENX TECHNOLOGIES..51
OTSUKA HOLDINGS CO LTD-0.12%25 562
SUN PHARMACEUTICAL IND..3.69%23 724
ONO PHARMACEUTICAL CO...-6.90%12 643
SHANGHAI FOSUN PHARMAC..32.54%10 569
ASPEN PHARMACARE HOLDI..-2.70%9 511
More Results